Abstract:Background: As one of the most common causes of death in advanced non-small cell lung cancer (NSCLC), brain metastases (BM) have attracted attention and debate about treatment options, especially for patients with negative driver genes or resistance to targeted agents.Therefore, we conducted a meta-analysis to investigate the potential benefit of different therapeutic regimens for intracranial lesions in non-targeted therapy NSCLC patients.Methods: A comprehensive search was conducted in databases including PubMed, Embase, and the Cochrane Library.The primary endpoints included the intracerebral objective response rate (icORR) and intracerebral progression-free survival (iPFS) in patients with BM.Results: Thirty-six studies involving 1,774 NSCLC patients with baseline BM were included in this metaanalysis.Antitumor agents plus radiotherapy (RT) showed the most significant synergistic effects; the highest pooled icORR that appeared in the combination of immune checkpoint inhibitor (ICI) and RT was 81% [95% confidence interval (CI): 16-100%], and the median iPFS was 7.04 months (95% CI: 2.54-11.55months).The pooled icORR and median iPFS of RT plus chemotherapy were 46% (95% CI: 34-57%) and 5.7 months (95% CI: 3.90-7.50months), respectively.The highest median iPFS in nivolumab plus ipilimumab plus chemotherapy was 13.5 months (95% CI: 8.35-18.65 months).ICI plus chemotherapy also showed potent antitumor activity in BM, with a pooled icORR of 56% (95% CI: 29-82%) and a median iPFS of 6.9 months (95% CI: 3.20-10.60months).Notably, the subgroup analysis indicated that the pooled icORR of patients in programmed cell death-ligand 1 (PD-L1) (≥50%) who received ICI was 54% (95% CI: 30-77%), and that of patients who received first-line ICI was 69.0% (95% CI: 51-85%).Conclusions: ICI-based combination treatment provides a long-term survival benefit for non-targeted therapy patients, with the most significant benefits observed in improving icORR and prolonging overall survival (OS) and iPFS.In particular, patients who received first-line treatment or who were PD-L1-positive had a more significant survival benefit from aggressive ICI-based therapies.For patients with a PD-L1negative status, chemotherapy plus RT led to better clinical outcomes than other treatment regimens.These innovative findings could help clinicians to better select therapeutic strategies for NSCLC patients with BM.

Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review

Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis

SRS in Combination with Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases.

Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis

Melanoma brain metastases - Interdisciplinary management recommendations 2020

Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases

Delayed and Concurrent Stereotactic Radiosurgery in Immunotherapy-Naïve Melanoma Brain Metastases

A Bayesian network meta-analysis of whole brain radiotherapy and stereotactic radiotherapy for brain metastasis.

Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review

Current and emerging options for patients with melanoma brain metastases

Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases

Efficacy of Different Therapies for Brain Metastases of Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Meta-analysis and evaluation of brain metastases tumor treatment model

Stereotactic Radiosurgery Combined with Targeted Therapy for Brain Metastasis: A Systematic Review and Meta-Analysis

A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases

Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 1: Diagnosis, Prognosis, Symptom Control, and Local Treatment

Comparison of Surgical Resection and Stereotactic Radiosurgery in the Initial Treatment of Brain Metastasis

Survival and Prognostic Factors for Patients with Melanoma Brain Metastases in the Era of Modern Systemic Therapy.

A Network Meta-Analysis of Curative Effect of Different Treatment Methods on Patients with Brain Metastasis of Breast Cancer

Meta-analysis of stereotactic radiosurgery with or without whole-brain radiotherapy for patients presenting brain metastases